generated from alshedivat/al-folio
-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathpapers.bib
57 lines (54 loc) · 5.33 KB
/
papers.bib
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
---
---
@article{firth2015functional,
title = {Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs},
author = {Firth, Amy L. and Menon, Tushar and Parker, Gregory S. and Qualls, Susan J. and Lewis, Benjamin M. and Ke, Eugene and Dargitz, Carl T. and Wright, Rebecca and Khanna, Ajai and Gage, Fred H. and Verma, Inder M.},
year = {2015},
month = {September},
journal = {Cell Reports},
volume = {12},
number = {9},
pages = {1385--1390},
publisher = {Elsevier},
doi = {10.1016/j.celrep.2015.07.062},
url = {https://doi.org/10.1016/j.celrep.2015.07.062},
issn = {2211-1247},
selected={true},
abstract = {Lung disease is a major cause of death in the United States, with current therapeutic approaches serving only to manage symptoms. The most common chronic and life-threatening genetic disease of the lung is cystic fibrosis (CF) caused by mutations in the cystic fibrosis transmembrane regulator (CFTR). We have generated induced pluripotent stem cells (iPSCs) from CF patients carrying a homozygous deletion of F508 in the CFTR gene, which results in defective processing of CFTR to the cell membrane. This mutation was precisely corrected using CRISPR to target corrective sequences to the endogenous CFTR genomic locus, in combination with a completely excisable selection system, which significantly improved the efficiency of this correction. The corrected iPSCs were subsequently differentiated to mature airway epithelial cells where recovery of normal CFTR expression and function was demonstrated. This isogenic iPSC-based model system for CF could be adapted for the development of new therapeutic approaches.}
}
@article{ramaswamy2018autologous,
title = {Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX},
author = {Ramaswamy, Suvasini and Tonnu, Nina and Menon, Tushar and Lewis, Benjamin M. and Green, Kevin T. and Wampler, Derek and Monahan, Paul E. and Verma, Inder M.},
year = {2018},
month = {May},
journal = {Cell Reports},
volume = {23},
number = {5},
pages = {1565--1580},
publisher = {Elsevier},
doi = {10.1016/j.celrep.2018.03.121},
url = {https://doi.org/10.1016/j.celrep.2018.03.121},
issn = {2211-1247},
selected={true},
abstract = {Hemophilia B is an ideal target for gene- and cell-based therapies because of its monogenic nature and broad therapeutic index. Here, we demonstrate the use of cell therapy as a potential long-term cure for hemophilia B in our FIX-deficient mouse model. We show that transplanted, cryopreserved, cadaveric human hepatocytes remain functional for more than a year and secrete FIX at therapeutic levels. Hepatocytes from different sources (companies and donors) perform comparably in curing the bleeding defect. We also generated induced pluripotent stem cells (iPSCs) from two hemophilia B patients and corrected the disease-causing mutations in them by two different approaches (mutation specific and universal). These corrected iPSCs were differentiated into hepatocyte-like cells (HLCs) and transplanted into hemophilic mice. We demonstrate these iPSC-HLCs to be viable and functional in mouse models for 9--12 months. This study aims to establish the use of cells from autologous and heterologous sources to treat hemophilia B.}
}
@article{lewis2024larp4,
title = {LARP4 is an RNA-binding protein that binds nuclear-encoded mitochondrial mRNAs to promote mitochondrial function},
author = {Lewis, Benjamin M. and Cho, Chae Yun and Her, Hsuan-Lin and Mizrahi, Orel and Hunter, Tony and Yeo, Gene W.},
journal = {RNA},
volume = {30},
number = {3},
pages = {223--239},
year = {2024},
month = {February},
doi = {10.1261/rna.079799.123},
publisher = {Cold Spring Harbor Laboratory Press for the RNA Society},
selected={true},
abstract = {Mitochondria-associated RNA-binding proteins (RBPs) have emerged as key contributors to mitochondrial biogenesis and homeostasis. With few examples known, we set out to identify RBPs that regulate nuclear-encoded mitochondrial mRNAs (NEMmRNAs). Our systematic analysis of RNA targets of 150 RBPs identified RBPs with a preference for binding NEMmRNAs, including LARP4, a La RBP family member. We show that LARP4's targets are particularly enriched in mRNAs that encode respiratory chain complex proteins (RCCPs) and mitochondrial ribosome proteins (MRPs) across multiple human cell lines. Through quantitative proteomics, we demonstrate that depletion of LARP4 leads to a significant reduction in RCCP and MRP protein levels. Furthermore, we show that LARP4 depletion reduces mitochondrial function, and that LARP4 re-expression rescues this phenotype. Our findings shed light on a novel function for LARP4 as an RBP that binds to and positively regulates NEMmRNAs to promote mitochondrial respiratory function.},
issn = {1469-9001},
pmid = {38164626},
pmc = {PMC10870378},
keywords = {La module protein, RNA-binding protein, eCLIP, mitochondria, translation},
grant = {R01 CA082683/CA/NCI NIH HHS/United States, R01 CA080100/CA/NCI NIH HHS/United States, T32 GM007240/GM/NIGMS NIH HHS/United States, U41 HG009889/HG/NHGRI NIH HHS/United States, U24 HG009889/HG/NHGRI NIH HHS/United States, R01 HG004659/HG/NHGRI NIH HHS/United States, R35 CA242443/CA/NCI NIH HHS/United States, P30 CA014195/CA/NCI NIH HHS/United States},
url = {https://doi.org/10.1261/rna.079799.123}
}